

Estrogen Replacement in Turner Syndrome: Literature Review and Practical Considerations

Karen O. Klein,^{1,2} Robert L. Rosenfield,³ Richard J. Santen,⁴ Aneta M. Gawlik,⁵ Philippe F. Backeljauw,⁶ Claus H. Gravholt,^{7,8} Theo C. J. Sas,⁹ and Nelly Mauras¹⁰

¹University of California, San Diego, California; ²Rady Children's Hospital, San Diego, California 92123; ³The University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637; ⁴University of Virginia, Charlottesville, Virginia 22904; ⁵Department of Pediatrics and Pediatric Endocrinology, School of Medicine in Katowice, Medical University of Silesia, 40-752 Katowice, Poland; ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229; ⁷Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 8000 Aarhus C, Denmark; ⁸Department of Molecular Medicine, Aarhus University Hospital, 8000 Aarhus C, Denmark; ⁹Erasmus Medical Center and Sophia Children's Hospital Rotterdam, 3015 CE Rotterdam, The Netherlands; and ¹⁰Nemours Children's Health System, Jacksonville, Florida 32207

Context: Most girls with Turner syndrome (TS) have hypergonadotropic hypogonadism and need hormonal replacement for induction of puberty and then for maintaining secondary sex characteristics, attaining peak bone mass, and uterine growth. The optimal estrogen replacement regimen is still being studied.

Evidence Acquisition: We conducted a systematic search of PubMed for studies related to TS and puberty.

Evidence Synthesis: The goals of replacement are to mimic normal timing and progression of physical and social development while minimizing risks. Treatment should begin at age 11 to 12 years, with dose increases over 2 to 3 years. Initiation with low-dose estradiol (E₂) is crucial to preserve growth potential. Delaying estrogen replacement may be deleterious to bone and uterine health. For adults who have undergone pubertal development, we suggest transdermal estrogen and oral progestin and discuss other approaches. We discuss linear growth, lipids, liver function, blood pressure, neurocognition, socialization, and bone and uterine health as related to hormonal replacement.

Conclusion: Evidence supports the effectiveness of starting pubertal estrogen replacement with low-dose transdermal E₂. When transdermal E₂ is unavailable or the patient prefers, evidence supports use of oral micronized E₂ or an intramuscular preparation. Only when these are unavailable should ethinyl E₂ be prescribed. We recommend against the use of conjugated estrogens. Once progestin is added, many women prefer the ease of use of a pill containing both an estrogen and a progestin. The risks and benefits of different types of preparations, with examples, are discussed. (*J Clin Endocrinol Metab* 103: 1790–1803, 2018)

The 2017 updated guidelines from the International Turner Syndrome Consensus Group have been published in the *European Journal of Endocrinology* (1) and endorsed by the European Society of Endocrinology, the Endocrine Society, the Pediatric Endocrine Society,

the European Society for Pediatric Endocrinology, the European Society of Human Reproduction and Embryology, the American Academy of Pediatrics, and the Society for Endocrinology (United Kingdom). The American Heart Association and European Society of

Cardiology also had official delegates at the meeting. The present paper expands on those guidelines specifically relating to puberty and estrogen replacement.

Turner syndrome (TS) defines phenotypic females who have one X chromosome and complete or partial absence of the second X chromosome. TS is characterized by physical features, including a classic facial appearance, neck webbing, short stature, and lymphedema, as well as ovarian insufficiency, sensorineural hearing loss, congenital cardiovascular disease, renal anomalies, some neurodevelopmental disorders, and increased risk of thyroid and celiac diseases. TS affects 25 to 50 girls per 100,000, and there is a very broad clinical spectrum of presentation. Some individuals have all the aforementioned features and others have minimal features, with or without short stature and ovarian insufficiency. The karyotype in TS ranges from complete 45,X to forms of mosaicism in which there is a normal (*i.e.*, 46,XX or 46,XY) cell line, and an abnormal second (or third) cell line (2).

TS is usually accompanied by hypergonadotropic hypogonadism due to gonadal dysgenesis and ensuing primary or secondary amenorrhea. Therefore, most patients with TS will need hormonal replacement therapy, first for induction of puberty and then for maintaining secondary sex characteristics, attaining peak bone mass, and normalizing uterine growth for possible pregnancy later. This review focuses primarily on estrogen hormone replacement in the care of girls with TS.

The optimal estrogen replacement therapy regimen to induce pubertal development and maintain beneficial effects in adults is still being studied. A substantial body of literature to date supports the effectiveness and theoretical benefits of starting pubertal estrogen replacement with low-dose transdermal (TD) estrogen, although, to our knowledge, there is no study to date of TD use from initiation of puberty until adulthood. Theoretical benefits of TD use include the more physiologic route of delivery, avoiding first-pass effects in the liver that include the accumulation of unphysiologic estrogens observed after the oral route (3), and avoiding effects associated with a procoagulation state (4) and increased risk of stroke (5).

We review estrogen forms, timing of replacement, dosing, route of administration, duration of treatment, and monitoring of treatment. We also review evidence relevant to optimizing the outcome and minimizing the risk of estrogen replacement in puberty as regards growth, lipids, liver health, bone health, uterine health, and thrombosis risk, as well as socialization and neurocognitive benefits.

Spontaneous Puberty in Girls With TS

Approximately one-third of girls with TS have spontaneous breast development that may progress to menarche,

occurring most often in girls with mosaicism (6, 7). Regular menstrual cycles occur in ~6% (8) of these young women.

Laboratory Markers of Ovarian Function

Elevated concentrations of gonadotropins, luteinizing hormone (LH), and, particularly, follicle-stimulating hormone (FSH) indicate ovarian failure (9, 10). FSH concentrations are higher in girls with 45,X karyotype compared with those with mosaic karyotype. LH and FSH levels in girls with TS are elevated after birth, then decline to levels similar to girls with normal ovarian function during mid childhood, and rise again in the peripubertal years (9, 11) or at the time of loss of previous ovarian function. Low anti-Müllerian hormone (AMH) levels and undetectable inhibin B levels have been reported to predict ovarian failure in TS (9, 12). In one study, 70 girls with TS and 2406 girls without TS had LH, FSH, and inhibin B concentrations measured before estrogen treatment (9). Ovarian function was related to whether girls had 45,X or a mosaic karyotype. According to the study data, undetectable inhibin B may predict the absence of spontaneous puberty, but the specificity was low. AMH in 120 girls with TS predicted no ovarian function when levels were <4 pmol/L (0.56 ng/mL) and predicted ovarian function when levels were >19 pmol/L (2.66 ng/mL) (12).

Treatment Options for Induction of Puberty and Maintenance of Feminization

Estrogen forms available for replacement

Estradiol (E_2) is the natural form of estrogen that is secreted and binds to the estrogen receptor in humans (13). Ethinyl estradiol (EE) is a very potent synthetic E_2 analog that is not metabolized to E_2 . It binds to estrogen receptors α and β . EE has an ethinyl group covalently attached at the 17 α -position. EE is taken up in unmodified form and retained by estrogen target tissues for a longer time than is E_2 . The E_2 precursor estrone acts after being metabolized to E_2 . Equine estrogens, the major components of the widely used conjugated equine estrogens (CEEs), consist of >100 forms of estrogens of different receptor affinity and potency. Estrogens are metabolized in the liver by microsomal cytochrome P-450 with aromatic hydroxylation at either the C2 or C4 position as the major route. Other pathways include formation of glucuronide conjugates and sulfation (14–16).

Table 1 lists commonly available, lower-dose estrogen treatments for pubertal induction and considerations for their use. Table 2 lists some common progestin and estrogen/progestin combination replacement options after pubertal

Table 1. Some Common Low-Dose Estrogen Treatment Options for Pubertal Induction in TS and Considerations for Use

Preparation ^a	Doses Available, Frequency, Route	Starting Dose at Puberty	Dose Increase Approximately Every 6 Mo to Adult Dosing	Considerations for Use
Transdermal options (some brands)		3–7 $\mu\text{g}/\text{d}$	25–100 $\mu\text{g}/\text{d}$	See text on applying patches
Menostar (Bayer) (matrix)	14 μg weekly TD	One-half patch weekly	Only used for low dosing, not full replacement	Easiest way to give low dose; once a week dosing
Vivelle Dot (Novartis) (matrix)	25, 37.5, 50, 75, 100 μg twice weekly	One-quarter patch weekly, or one patch per month (no patch other 3 weeks)	25–100 μg twice weekly	Designed for twice-weekly dosing, but can give once per week to increase dose more slowly
Vivelle Mini (matrix)	25, 37.5, 50, 75, 100 μg twice weekly	Too small to cut consistently	25–100 μg twice weekly	Smaller size patch, but not smaller dosing
Generic (different brands in different countries)	25, 37.5, 50, 75, 100 μg twice weekly	One-quarter patch weekly, or one patch per month (no patch other 3 wk)	25–100 μg twice weekly	Once-weekly dosing can be used.
Estraderm (matrix)	50, 100 μg twice weekly	Not small enough to initiate puberty	50–100 μg twice weekly	Cannot use to initiate puberty
E ₂ gel		0.25 mg per pump	One pump daily	Only available in some countries at the low dose
Estragel (Ascend), 0.06%	0.75 mg E ₂ per pump			
Divigel (Vertical), 0.1%	0.25, 0.5, 0.1 mg E ₂ per pump			
Oral options				
17 β -E ₂ [e.g., Estrace (Allergan), Cetura (ACE)]	0.5, 1, 2, 4 mg/d	One-half pill daily	1–4 mg/d	Cheapest option, brands vary by country
EE		2 $\mu\text{g}/\text{d}$	10–20 $\mu\text{g}/\text{d}$	Not available in many countries
Premarin (Pfizer) (a CEE)	0.3, 0.625, 0.9, 1.25 mg/d	One-half pill daily	0.625–1.25 mg/d	Not available in many countries, not recommended based on safety
Depot options				
Depot E ₂ (E ₂ cypionate)	5 mg/mL	0.2 mg/mo	2 mg/mo	Not available in Europe

^aThe reader should be aware that availability and trade names differ among countries. The list is not all inclusive.

induction is complete. The reader should be aware that availability and trade names differ among countries. The list is not all inclusive. We present data from various routes and preparations but list other preparations for reference, with the caution that studies have not been done in TS with each preparation listed. Table 3 summarizes published low-dose estrogen treatments for puberty induction in TS.

Timing and dose

The goals of replacement are to mimic the normal progression of puberty in girls while maximizing growth potential and minimizing risks. Delaying estrogen replacement may be deleterious to bone, uterine, and psychosocial health parameters (28). To mimic normal physical and social development, initiation of treatment should begin at 11 to 12 years of age if levels of gonadotropins are elevated or AMH concentration is low.

LH and FSH levels may be measured yearly starting at age 11, based on average age of pubertal onset. If gonadotropin concentrations are normal for age, observation for spontaneous puberty is appropriate, with future replacement therapy if gonadal failure occurs.

Incremental dose increases at ~6-month intervals can mimic the normal pubertal tempo until adult dosing is reached over 2 to 3 years. This theoretically translates into a 25% to 100% increase in dose every 6 months for four to six dose changes between the initiation and adult doses portrayed in the Table 1. However, no studies to date have rigorously studied outcomes in relation to the rate of dose increase for the different preparations.

In general, the studies summarized in Table 3 report onset of breast buds within 6 months in most girls (17, 18, 22, 23, 27). Each of these regimens results in pubertal stage 4 breasts in an average of 2.25 years, which is

Table 2. Some Common Progestin and Estrogen/Progestin Combination Replacement Options After Pubertal Induction Is Complete

Adding Progestin Options	Doses Available, Frequency and Route	Not Needed to Initiate Puberty	Add Once Bleeding Occurs or After 2 Years	Notes
Medroxyprogesterone acetate	10 mg/d for 10 d		Give with TD E ₂ or alone for 10 d	
Micronized progesterone (Prometrium; AbbVie)	100 mg/d		Give continuously with TD E ₂	Less breast cancer risk long term
Combined E ₂ /progestin sequential patch (some brand options)		Do not use to initiate puberty		
Climara Pro (Bayer)	E ₂ 0.045 mg and levonorgestrel 0.015 mg/24 h		One patch weekly	
Combipatch (Noven)	E ₂ 0.045 mg and norethidrone 0.14 or 0.25 mg/24 h		One patch weekly	
Evo-Sequi (Janssen)	E ₂ 50 µg and norethisterone acetate 170 µg/24 h		Two patches weekly	
Combined E ₂ /progestin sequential pills		Do not use to initiate puberty		
Trisequens (Novo Nordisk)	E ₂ 2 mg and norethisterone acetate 1 mg		1 pill/d	
Divina plus	Estradiolvalerate 2 mg and medroxyprogesterone acetate 10 mg		1 pill/d	
Femoston (Mylan)	E ₂ and dydrogesterone 1/10 or 2/10 mg		1 pill/d	
Oral contraceptive pills ^a		Do not use to initiate puberty		

^aThere are multiple types of oral contraceptive pills, which differ in estrogen dose, sequential vs continuous, and type and dose of progestin. The reader is referred to the text to outline general principles.

similar to that in girls with TS who have spontaneous puberty (1.9 years), as well as in the general population (23).

Girls with TS are very short and have a very short adult-height potential, typically 20 cm less than the average female population in all countries studied. Growth hormone (GH) treatment is US Food and Drug Administration–approved therapy to promote growth in these girls, and the earlier it is started, the better the growth promotion. However, the expectations of intervention are modest. In general, GH therapy results in a net gain of 1 cm/y of treatment (20, 29). In girls in whom GH treatment has been delayed, consideration of initiation of GH prior to low-dose estrogen is particularly important to optimize growth. There are no data to support the specifics of timing in such cases; rather it is a matter of individualized judgment, balancing the desire for taller height vs the desire for more rapid feminization. When height is a greater concern, often GH treatment can be initiated before low-dose E₂; however, we recommend that E₂ not be delayed past 14 years of age. When feminization is a greater concern, GH and E₂ can be started simultaneously.

Initiation with low doses of E₂ is crucial to preserve growth potential even if GH treatment has already been initiated. Very low doses of EE and E₂ do not interfere with growth response to GH therapy when started at ≤12 years of age (21, 24).

Progestins

Patients with TS have a normal uterus anatomy, so progestin must be added once breakthrough bleeding occurs, or after 2 years of E₂ treatment, to minimize the risks of endometrial hyperplasia, namely, irregular bleeding and endometrial cancer associated with prolonged unopposed estrogen (30, 31).

Progestins are divided into several classes (Table 4) and individual agents can bind to the progesterone receptor as well as the androgen, glucocorticoid, and mineralocorticoid receptors (32). Each progestin exerts differential effects on these various receptors and, accordingly, unique, nonclass action effects. In addition to the progestational effects, the 19-nor-progesterone derivatives are associated with androgenic action, medroxyprogesterone acetate with glucocorticoid-agonistic action, and drospirenone with antiandrogenic and anti-mineralocorticoid actions, whereas progesterone is more specific to progestational effects. The combined oral contraceptives (OCs) containing progestins are divided into first-, second-, third-, and fourth-generation OCs. First-generation OCs contain 50 µg of the estrogen mestranol and the progestogen norethynodrel (*e.g.*, Enovid; Searle). Most later-generation pills use 20 to 35 µg of EE as the estrogen. Second-generation progestogens include norethindrone; its acetate, ethynodiol diacetate; and levonorgestrel.

Table 3. Summary of Published Studies of Low-Dose Estrogen Treatment of Puberty Induction in TS

Reference, Year	Subjects	Estrogen Treatment, Route and Dose	Outcomes	Height
Ankarberg-Lindgren <i>et al.</i> (17), 2001	n = 8 girls with TS (age 12–16 y) and n = 7 with other hypogonadism	TD E ₂ 6–18 μg given just 12 h overnight	B2 in 3–6 mo in 75% of girls on low-dose, and B3 in 2 y on higher dose; TD dose correlated with serum E ₂ (P < 0.001)	No height data
Van Pareden <i>et al.</i> (18), 2003	n = 60 girls with TS with or without spontaneous puberty	Oral E ₂ 5 μg/kg × 2 y → 7.5 μg/kg × 1 y → 10 μg/kg after 4 y GH	B2 onset in 0.2 y on average	No negative effect on height or growth velocity vs spontaneous puberty
Piippo <i>et al.</i> (19), 2004	n = 23 girls with TS	E ₂ gel 0.1 mg × 1 y → 0.2 mg × 1 y → 0.5 mg × 1 y → 1 mg × 1 y → 1.5 mg × 1 y	Pubertal advance about one stage per year treatment with 50% B2 at 6 mo	Adult height 153.1 ± 4.8 cm (mean ± standard deviation)
Soriano-Guillen <i>et al.</i> (20), 2005	n = 704 girls with TS with or without spontaneous puberty	Oral EE 1–5 μg/d; oral E ₂ 0.5 mg/d; TD one-quarter of a 25-μg/d patch	No data on rate of pubertal progression	Patients receiving TD E ₂ were taller than those receiving oral formulation by an average 2.1 cm, but shorter than spontaneous
Rosenfield <i>et al.</i> (21), 2005	n = 14 girls with TS, compared with NCGS registry, age 12–15 y	Depot E ₂ 0.2 mg/mo with increase of 0.2 mg every 0.5 y; GH also given 0.05 mg/kg/d	Half of girls B1 → B2 in 0.5 y, and increased one stage per 0.5 y with each 0.2-mg increase in dose. with 1 mg dose: 100% B3–B5 by 2 y and menarche in 62.5% by 2.5 y	Lowest dose had greatest GV; FH > PAH at start of treatment; FH > GH alone, growth not as good as in TS with spontaneous puberty
Nabhan <i>et al.</i> (22), 2009	n = 12 girls with TS, age 11.3–17 y	Oral CEE (0.3–0.45 mg/d) vs TD (25 μg/d for 6 mo → 37.5 μg/d for 6 mo)	B3–4 by 1 y in 83%; no change in 17%; TD group had greatest increase in spine density, BMD, uterine length and volume	No height data
Bannink <i>et al.</i> (23), 2009	n = 56 girls with TS, age 11–18 y	Oral E ₂ (5 μg/kg/d) × 2 y, with progression to 7.5 and 10 μg/kg/d	Breast stage progressed in same timing as average Dutch population: B1 → B2 in 0.2 y; B1 → B4 in 2.1 y	No height data
Torres-Santiago <i>et al.</i> (3), 2013	n = 40 girls with TS, age 13–20 y	Oral E ₂ (average, 2 mg) vs TD E ₂ (average, 0.1 mg), dose titrated to plasma E ₂	No difference in body composition, BMD, or lipids between groups	No height data
Ross <i>et al.</i> (24), 2011; Quigley <i>et al.</i> (25), 2014	n = 144 girls with TS analyzed for growth; n = 123 girls with TS analyzed for puberty, age 5–12.5 y	Oral EE: 25 ng/kg/d, 5–8 y; 50 ng/kg/d, >8–12 y; >12 y, escalating from 100 ng/kg/d; with or without GH	EE dose decreased for breast development before age 12 y or vaginal bleeding before age 14 y; age of menarche similar to general population; earlier breast development for girls who received the early low dose	GH plus EE group height SDS increase of 0.58 compared with increase of 0.26 in GH alone
Perry <i>et al.</i> (26), 2014	n = 92 girls with TS, age 7–13 y	Oral EE: 2 μg/d year 1; 4 μg/d year 2; 6/8/10 μg/d increases every 4 mo in year 3	B1 → B2 in 0.65 y and to B4 in 2.25 y	Growth reported to be not as good as with depot E ₂
Çakir <i>et al.</i> (27), 2015	n = 13 girls with TS, age 11–17 y	Oral E ₂ 0.5 mg/d vs TD 4.5 μg/d	B1 → B3–4 in 1 y	BA advanced less with TD (ΔCA/ΔBA 2.2 vs 0.58; P = 0.005); GV greater on TD at 1 y (4.35 vs 3.8; P = 0.022)

Abbreviations: B2, breast stage 2; B3, breast stage 3; B4, breast stage 4; BA, bone age; CA, chronologic age; FH, final height; GH, growth hormone; GV, growth velocity; PAH, predicted adult height; Δ, change in; SDS, standard deviation score.

Third-generation progestogens include desogestrel, norgestimate, and gestodene. Fourth-generation pills include drospirenone. All OCs increase the risk of venothrombotic episodes (VTEs). A recent guideline (33) concluded that combinations of EE with the third- or fourth-generation progestogens have a slightly higher risk of VTE than those containing first- and second-generation

components. Micronized progesterone is associated with a lesser risk (34).

Regimens of estrogen plus a progestin are either combined sequentially with an estrogen for 21 to 25 days and the progestin for only 10 to 14 days, or combined with both sex steroids continuously. The estrogen is given for up to 21 to 25 days to cause the endometrium to

Table 4. Classification of Progestins

Classification	Progestin
Natural	Progesterone
Synthetic	
Pregnane derivatives	
Acetylated	Medroxyprogesterone acetate Megestrol acetate Cyproterone acetate
Nonacetylated	Chlormadinone acetate Dydrogesterone Medrogestone
19-Norpregnane derivatives	
Acetylated	Nomegestrol acetate Nesterone
Nonacetylated	Demegestone Promegestone Trimegestone
Nor-testosterone	
Ethinylated estranes	Norethindrone (norethisterone) Norethindrone acetate Ethinodiol diacetate Norethynodrel Lynestrenol Tibolone
13-Ethylgonanes	Levonorgestrel Desogestrel Norgestimate Gestodene
Nonethinylated	Dienogest Drospirenone

become proliferative; the progestin in combination with the estrogen induces the luteal phase of the endometrium. Ten days of a progestin each month protects against estrogen-induced endometrial hyperplasia, and 3 months of combined continuous estrogen plus a progestin is also protective (35). The combined sequential regimens are associated with menstruation and are preferred in younger women, whereas the combined continuous regimens prevent uterine bleeding, an attractive factor for older women. Intrauterine devices containing a progestin block endometrial hyperplasia and unwanted bleeding, can be used along with an estrogen, and can be especially attractive for women with bleeding problems who are taking either TD or oral combined formulations. Availability of products varies by country (Table 2).

Route: Oral vs TD Comparisons

E₂ is normally secreted into the systemic circulation, the liver receives the same dose as other somatic tissues, and a systemic route of estrogen delivery is physiologic (13). In contrast, estrogen given orally reaches the systemic circulation only after absorption into the portal venous system and metabolism by the liver, thus exposing the liver to a greater dose of estrogen than the rest of the body.

TD E₂ is the most widely used of the physiologic E₂ options, but the commercially available forms (patches

and gels) are designed for the adult female market and, thus, the lowest-dose forms are four- to 10-fold greater than are appropriate to deliver early pubertal E₂ blood levels. The main strategies that have been advocated to fractionate TD E₂ in a manner appropriate for early puberty are based on different perspectives on normal pubertal E₂ physiology.

Currently, the lowest-dose patch commercially available delivers 14 µg/d E₂, and the most widely used low-dose patches deliver 25 µg/d. One method to deliver lower doses is to cut the patch in smaller pieces. Patches with a matrix design can be easily cut, whereas patches with a reservoir technology should not be cut. The disadvantages of cutting patches are that handling the smaller pieces may be difficult and cutting the patches is not recommended by the products' labels. However, there is clinical experience with this, especially in Scandinavia. There, a group showed that a fractionated patch dose (one-quarter patch of a 25-µg dose approximately equals 6.2 µg or even less) applied overnight mimicked the normal, early-morning serum E₂ peak and fell back to baseline within a few hours of patch removal (17). If one does not want to cut the patches, it has also been proposed that cyclic administration of patches, commencing with the application of a 14- to 25-µg patch for 1 week monthly may achieve similar results, although we have no data at this time with this method (21, 36). This proposal comes from an expert committee of the Pediatric Endocrine Society, which recommended initiating cyclic therapy with 25 µg/d TD E₂ for 1 week and then gradually increasing the duration of patch application to 3 weeks per month before increasing the patch size. Support for this recommendation includes not only considerations of convenience and manufacturer recommendations against patch fractionation but evidence of efficacy of cyclic administration of depot systemically delivered E₂ (21). Evidence also exists that estrogenization of the vaginal mucosa lags behind changes in serum E₂ by about 1 week (3, 37), suggesting that the pituitary-ovarian axis activity normally commences with attenuated cyclicality (38). Expert discussion of this method, however, suggests that 1 week with and 3 weeks without E₂ would cause such variable changes in plasma E₂ concentrations during these 4 weeks that may not mimic physiology. Additional data are needed before conclusions can be made regarding the optimum mode of patch-application recommendation.

Two studies by Torres-Santiago *et al.* and Taboada *et al.* have directly compared the TD and oral routes of E₂ administration in teenagers (3, 39). The pharmacokinetics and pharmacodynamics of different doses of E₂ given orally vs transdermally were examined in a group of girls with TS. TD E₂ results in E₂, E₁, and bioestrogen

concentrations that are closer to normal and achieve greater suppression of LH and FSH in lower doses compared with normally menstruating girls without TS (40). The metabolic effects of oral vs TD E₂ were additionally compared in 40 late-teen girls with TS followed for 1 year (3). The researchers found no differences in body composition, bone mineralization, or plasma lipids when the plasma E₂ levels were titrated to those of normally menstruating adolescents. Although no metabolic differences were observed, oral estrogen was associated with a marked increase in conjugated estrogen precursors such as estrone sulfate and increased serum estrogenic bioactivity. This is concerning in the context of the increased thromboembolic risk observed with oral estrogen in epidemiological studies, although there are no data to suggest that such problems are present in TS (discussed later in this article). Some European countries have approved an E₂ gel (Table 1), but it is very difficult to give a small enough dose for pubertal induction, and there is only one study with data from girls with TS (19).

Depot route

Results of a randomized controlled trial showed that early, depot E₂ monthly injections at very low doses stimulated normal pubertal growth and development in conjunction with GH treatment (21). This remains a viable alternative in the United States, although it is less attractive because of the pain of injection.

Practical Considerations

Estrogen treatment is crucial for girls with TS, first to induce puberty and then to maintain healthy levels for all the reasons described here. Individualizing treatment to optimize compliance is important, and helping girls understand how easy it is to help them have breast development consistent with their peers should be encouraged. Based on literature and theoretical principles presented here, we suggest the following practical approach to feminize girls with TS: initiate puberty with low-dose TD E₂, when available, starting with half of a 14- μ g patch applied weekly, or a whole 14- or 25- μ g patch for 1 week per month at age 11 to 12 years (Table 1), and increase every 6 to 12 months based on response and growth potential. When not available, or for physician or patient alternative preference, consider approaches discussed earlier in this article and listed in Tables 1 and 2.

For the adult patient with TS, no long-term studies have assessed the optimal dose, route, or duration of E₂ treatment, to our knowledge. Our recommendations are based on available data from women with TS and from other hypogonadal patients. The effects of hormone treatment in TS may be different from what is observed in

other patient populations, and caution is needed when extrapolating data from postmenopausal studies (40). With those cautions, the type and route must be negotiated, taking into account the preference of the patient, the size of the uterus (for possible oocyte donation), bone and body composition assessed by dual-energy X-ray absorptiometry, blood pressure, and quality of life, as well as other considerations (discussed later in this article). Adult TD replacement doses of 50 to 150 μ g/d or oral replacement doses of 2 to 4 mg of E₂ will often be sufficient. Oral progestin for 10 days per month (combined sequential approach) or continuous progestin regimens are suggested [analogous to the combined/continuous methodology commonly used for menopausal hormone therapy (41)]. If bleeding irregularities occur or if the patient prefers, an intrauterine progestin-coated device can be used together with either continuous oral or TD E₂. This will reduce bleeding irregularities and often abolish bleeding and the need for systemic progestin use. Close collaboration with a gynecologist with knowledge of TS is very useful.

Duration

Once adult replacement doses are reached, treatment should continue until the time of usual menopause, around age 51 to 53 years, when the risks vs benefits of continuing should be assessed, individualized, and reassessed annually (35, 41). Combined estrogen and progestin treatment duration is limited by increased risk of breast cancer (42); however, there are no clinical or epidemiological data relative to TS to suggest that breast cancer is a problem. Actually, breast cancer seems to occur less frequently among women with TS (1), although diminished overall estrogen exposure may be a factor. Estrogen therapy alone after menopausal age has a more favorable risk–benefit ratio, allowing more flexibility in duration, but is only indicated in women who have undergone hysterectomy (43). There often will be a continued need for education of the patient with TS to explain the beneficial effects of hormonal replacement therapy on multiple organ systems to maintain adherence to therapy.

Monitoring Treatment

Routine monitoring of serum LH or FSH levels is not recommended during estrogen treatment, because levels remain elevated in agonadal women until higher levels of estrogen are given (44). The suppression of gonadotropins was comparable after oral and TD E₂ use when doses were titrated to similar serum E₂ levels (3). E₂ measurement using a sensitive assay (*e.g.*, liquid or gas

chromatography with tandem mass spectrometry) allows dose titration if desired, though E₂ levels for optimal linear growth remain to be determined. Clinical assessment, patient satisfaction, patient age, and, often, residual growth potential are the primary determinants for dose increase. If potential for taller stature is still possible, girls may take lower estrogen doses for a longer time. If girls are already older at initiation, the duration until adult dosing may be shortened.

In adults, replacement TD doses of 50 to 200 µg/d typically allow women to reach normal adult plasma E₂ concentrations. The normal range of E₂ in cycling women is very wide, with early follicular phase levels as low as 20 to 40 pg/mL (~75 to ~150 pmol/L) and midcycle peak of 200 to 600 pg/mL (~730 to ~2200 pmol/L), and some experts replace to these levels (3). When oral estrogen is used, adult replacement doses of 2 to 4 mg of E₂ will result in normal circulating E₂ levels [*i.e.*, ~100 to ~155 pg/mL (~367 to ~568 pmol/L)] (44) and may lead to normal levels of FSH and LH in some women (44, 45). However, women with TS lack inhibin (46), so normalizing LH and FSH levels is not the goal *per se* (47, 48). Optimizing all the health benefits and minimizing the risks is the goal, and it is important to remember that this must be individualized.

Optimize Outcomes, Minimize Risks: Growth, Lipids, Liver, Bone Health, Uterine Health, and Thrombosis Risk

Estrogens and linear growth

Low-dose estrogen regimens do not appear to interfere with growth response to GH therapy when begun at 11 to 12 years of age at low doses (21, 24, 26, 49). Ultra-low dose oral EE (starting at 25 ng/kg/d at ages 5 to 12 years) in childhood TS has been reported but is not currently recommended, based on an increased risk of earlier thelarche and no proven benefit to growth or pubertal outcome (25).

A consistent effect of physiologic E₂ replacement on IGF-1 concentration has not been established (3). IGF-1 concentrations tended to be lower on oral than TD E₂ [-16 ± 12 vs 28 ± 12 ng/mL (mean \pm standard error) at 12 months; $P = 0.059$] (3), whereas an earlier study from the same group showed no change in IGF-1 concentration after oral or TD therapy (50). TD application caused a decrease in IGF binding protein-3 and GH binding protein compared with an increase in the former and unchanged level of the latter after oral administration (51). In contrast, contraceptive doses of oral EE are known to suppress IGF-1 (52, 53). In a small study ($n = 13$ girls), bone age advanced less when using TD E₂ than oral E₂ (change in chronological age divided by change in

bone age, 2.2 vs 0.58, respectively; $P = 0.005$). At the same time, growth velocity was greater when using TD E₂ than oral E₂ at 1 year (4.35 vs 3.8 cm/y, respectively; $P = 0.022$), suggesting overall better growth (17).

Estrogens and Metabolism

Lipids

Although there are theoretical reasons to be concerned about the relative systemic and hepatic hyperestrogenism of low-dose oral estrogens vs low-dose TD E₂, evidence thus far does not indicate that the hepatic effects on lipids or binding proteins cause an appreciable clinical difference between the two forms of treatment (Table 5) (3, 39, 54). With the exception of one study reporting significantly elevated high-density lipoprotein cholesterol after oral E₂ (54), there were no significant differences in lipids between groups with different routes of estrogen administration (3, 39).

Estrogen deficiency in TS is associated with elevated levels of intrahepatocellular lipids (62). Notably, whereas liver enzymes are elevated in untreated TS (45, 51, 63, 64), exogenous estrogen-progestin administered orally or transdermally reduces these levels (45, 52, 65). However, withdrawal of estrogen substitution did not influence liver enzyme levels (66, 67). There was no evidence of liver toxicity from estrogen replacement therapy (61).

Glucose and insulin

The risk of type 1 and type 2 diabetes mellitus is increased in patients with TS across all ages (68). However, there were no significant differences in glucose (3), insulin tolerance (57, 59), fasting insulin concentration, protein turnover and lipolysis (50), osteocalcin or highly sensitive C-reactive protein (3), body mass index, or waist-to-hip ratio (59, 60) between groups receiving TD vs oral estrogen treatment (Table 5). Glucagon and insulin levels (during oral glucose tolerance testing), as well as insulin resistance, tended to be lower after evening oral E₂ administration (0.3 to 0.5 mg/d) (58). Hyperinsulinemia was suppressed to normal by both EE and CEE. A recent study in 104 girls with TS who were followed up to 7 years after GH therapy showed no negative influence of GH treatment on β -cell function, which is also reassuring, because most of these girls continued on estrogen therapy (69).

Estrogens and bone density

Maintenance of bone health is crucial for women with TS. Delaying estrogen replacement is deleterious to bone health. Initiating and maintaining estrogen therapy during puberty and adulthood as outlined in this article is important for bone density accrual and prevention of

Table 5. Estrogen Treatment and Metabolic Outcome Data

Reference, Year	No. of Subjects	Treatment	Main Metabolic Measure Outcome
Jospe <i>et al.</i> (54), 1995	8	Oral E ₂ 100 ng/kg/d vs TD E ₂ 0.0125 mg/kg/d	Oral, but not TD, increased serum HDL
Gravholt <i>et al.</i> (55), 1998;	15 (oral)	Oral: 2 mg/d E ₂ days 1–22, plus 1 mg/d	No difference between oral and TD in insulin
Gravholt <i>et al.</i> (51), 1997	8 (TD)	norethisterone acetate days 13–22, and 1 mg/d E ₂ days 23–28 vs TD E ₂ 50 mg/d for 28 days plus oral 1 mg norethisterone days 13–22	sensitivity, body composition changes, 24-h ambulatory blood pressure, IGF-1, liver function test results, and lipid levels
Gussinyé <i>et al.</i> (56), 2000	12	TD E ₂ 100 µg/d	BMD and BMD z-score values significantly increased; no significant differences in BMI, calcium intake, and physical activity habits
Guttman <i>et al.</i> (57), 2001	17	CEE 0.625 mg/d vs EE 30 µg/d	Hyperinsulinemia was suppressed to normal by both EE and CEE Lipid profiles were normal on both regimens. PTH and 1,25-dihydroxyvitamin D levels increased while receiving HRT (EE > CEE), and phosphorus decreased Alkaline phosphatase, osteocalcin, and urinary deoxypyridinoline cross-links were high while off therapy; the former two suppressed to high-normal levels on the EE regimen, but not on CEE
Naeraa <i>et al.</i> (58), 2001	9	Morning oral E ₂ 6–11 µg/kg/d vs evening oral E ₂ 6–11 µg/kg/d	During OGTT in the morning, glucagon and insulin levels were lower after evening E ₂ administration, and insulin resistance tended to be lower
Alves <i>et al.</i> (59), 2006	9	CEE 0.625 mg/d vs TD E ₂ (gel) 1.5 mg/d	No difference in BMI, WHR, or insulin tolerance between CEE and TD E ₂ During TD, tendency toward increased total lean mass
Mauras <i>et al.</i> (50), 2007	11	Low-dose oral E ₂ 0.5 mg/d	LDL/HDL cholesterol responses were variable among groups
Taboada <i>et al.</i> (39), 2011	10	Low-dose TD E ₂ 0.0375 mg/d High-dose oral E ₂ 2.0 mg/d High-dose TD E ₂ 0.075 mg Oral E ₂ 0.5, 1, 2 mg/d for 2 weeks each vs TD E ₂ 0.025, 0.0375, 0.05 mg/d for 2 weeks each	Neither oral nor TD E ₂ adversely affected rates of protein turnover, lipolysis, and lipid oxidation rates or plasma lipids, fibrinogen, or fasting insulin concentrations
Torres-Santiago <i>et al.</i> (3), 2013	40	Oral E ₂ 2 mg vs TD E ₂ 0.1 mg	Similar fat-free mass, % fat mass, BMD accrual, lipid oxidation, resting energy expenditure rates No significant changes in lipids, glucose, osteocalcin, hs-CRP
Reinehr <i>et al.</i> (60), 2016	490	Oral vs TD (no details available)	Duration and dose of estrogens, route of administration did not correlate significantly to changes of BMI SDS

See Table 3 legend for expansion of other abbreviations.

Abbreviations: BMD, bone mineral density; BMI, body mass index; CE, conjugated estrogen; HDL, high-density lipoprotein; HRT, hormone replacement therapy; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; OGTT, oral glucose tolerance test; PTH, parathyroid hormone; WHR, waist-to-hip ratio.

fractures. In girls with TS, TD E₂ administration (2.5 to 37.5 µg/d) has been reported as better than CEE (0.3 to 0.45 mg/d) for spine bone mineral density (BMD) in one study [0.12 ± 0.01 vs 0.06 ± 0.01 g/cm² (mean \pm standard error); $P = 0.004$] (22). Findings of a recent study suggest a higher-than-usual oral dose (4 vs 2 mg) during early adulthood improves body composition (increased muscle mass) and increases bone formation markers, which, although BMD was not increased during the study period, in the long run could improve overall bone health (70).

Some adult women with TS prefer combined estrogen and progestin pill options for the sake of convenience (71). Few studies have directly compared TD estrogen regimens with oral regimens in women with premature ovarian insufficiency, including patients with TS. The better-powered studies indicated improved lumbar spine density on a physiological sex steroid–replacement regimen (100 to 150 µg E₂ daily plus 400 mg of vaginal progesterone 2 weeks per month) (48).

On the basis of these studies, the guidelines written by the European Society of Human Reproduction and

Embryology favored TD E₂ for women with premature ovarian failure and commented that OC pills may be appropriate for some women but effects on BMD are less favorable (72–74). More comprehensive long-term studies will be necessary to confirm these results and to examine fracture rates.

Estrogens and uterine growth

Data on the influence of different routes of estrogen therapy on uterine volume are still inconclusive because route, dose, age at onset of treatment, and duration of treatment all influence uterine growth (22, 23, 75–79). However, it is clear the longer the duration of treatment and the higher the dose of estrogen, the better the chances of normalizing uterine size, which is important only if pregnancy options are pursued. One study in 12 girls with TS reported uterine length was significantly greater with TD E₂ treatment (25 to 37.5 µg/d) compared with CEE [0.3 to 0.45 mg/d; 4.13 ± 0.39 vs 1.98 ± 0.39 cm (mean ± standard deviation), respectively; *P* = 0.003] and uterine volume greater [22.2 ± 4.4 vs 4.0 ± 4.4 mL (mean ± standard deviation), respectively; *P* = 0.02] (78). Higher-than-usual doses are often necessary before oocyte donation, where oral doses up to 8 mg have been used for up to 2 years to achieve satisfactory uterine growth (80).

Estrogens/progestin therapy and cardiovascular risk

Although, to our knowledge, there have been no studies in children, or in women with TS, we recommend against CEE use in view of thromboembolic and cardiovascular disease risks reported in postmenopausal women, especially in the first year of treatment using oral estrogen, and in women with existing risk factors like obesity (4, 5, 55, 81, 82).

E₂ replacement therapy, oral or TD, lowers blood pressure (55, 81, 82), although E₂ causes salt and water retention (83). This contrasts with EE-containing contraceptives, which raise blood pressure significantly unless they contain an anti-mineralocorticoid progestin (84).

Recent reports have indicated no increased risk of stroke with progesterone, pregnane derivatives, or nortestosterone derivatives (5, 85). However, norpregnane derivatives were found to increase risk (5). Studies have not been done in TS comparing various progestin options.

Several studies examining both oral E₂ and oral conjugated estrogens vs TD E₂ replacement in the postmenopausal setting have shown increased thromboembolic risk, especially in the first year of treatment in the oral group, that is more pronounced in women with existing risk factors such as obesity (5, 44, 86). Studies directly comparing thromboembolic risk in women with TS have not been done, to our knowledge.

Screening for thromboembolic risk, through measurement of Factor V Leiden and prothrombinase levels, should be done in girls with a personal or family history of VTE; however, routine screening is not recommended, and screening is done only to educate the family about risks, not to postpone estrogen therapy (87). TD estrogen is the preferred treatment in these girls.

Socialization and neurocognitive benefits

Estrogen replacement in girls with TS may improve motor speed and verbal and nonverbal processing time compared with placebo-treated patients with TS (88, 89). In adolescents with TS, oral estrogen therapy improved self-reported self-esteem and psychological well-being over time. At the same time, these patients' parents reported improvement in problem behaviors (90). Data on adults with TS have not been so optimistic. Adults with TS had relative difficulty with measures of spatial and perceptual skills, visual-motor integration, affect recognition, visual memory, attention, and executive function. These deficits were apparent in women with TS despite evidently adequate estrogen treatment (91, 92). Age of onset of puberty influenced sexual experience in one study (93) but not in another (94). A more recent follow-up report suggests that women with TS face more challenges in areas of sexual confidence and self-esteem (95).

The young women with TS who reached normal height and had age-appropriate pubertal development reported normal health-related quality of life; satisfaction with breast development (and height) had a positive influence on several health-related quality of life scales (96). Puberty should be induced at a physiologically appropriate age in patients with TS to optimize self-esteem, social adjustment, and timing of initiation of the patient's sex life. However, one study showed that neither estrogen use nor age of puberty influenced sexual function in patients with TS (94).

Oxandrolone effect on puberty

Oxandrolone is a nonaromatizable weak androgen with direct growth-promoting effects. Low-dose oxandrolone acted synergistically with GH to increase linear growth in several well-controlled studies (48, 97–99). However, oxandrolone may also increase hirsutism and clitoral size slightly, slow pubertal progression modestly (by 1.3 years), and delay menarche in response to estrogen replacement (100). These effects are usually minor and/or transient. Results of one study indicated normal adult breast size is subsequently attained as oxandrolone is discontinued and adult estrogen replacement is instituted (101). Pubic-hair stage was not affected. Therefore, a reasonable suggestion is that treatment with oxandrolone,

0.03 to 0.05 mg/kg/d (maximum, 2.5 mg/d), starting from the age of 10 years onward be considered as adjunctive therapy only in very short girls with TS (100, 102).

Future Research

Only limited data from random controlled trials are available now on girls with TS regarding estrogen treatment options, as discussed. There continues to be a paucity of data from girls and women with TS regarding the regimens discussed in this article and long-term compliance. Questions for future research include the following eight: (1) What is the optimal protocol for pubertal induction, including dose, route, and rate of progression? (2) What are the optimal circulating levels of E₂ during each phase of pubertal induction? (3) What is the optimal dosing, preparation, and timing of progestin-induced uterine bleeding? (4) How long should E₂ treatment be continued in women with TS? (5) What are the optimal method and timing for monitoring bone health in women with TS? (6) What is the optimal regimen to promote uterine growth? (7) If an OC is used for treatment, which are preferable in women with TS? and (8) What is the effect of OC pill placebo days on the hormonal milieu in women with TS?

Conclusion

In summary, we suggest that estrogen replacement should mimic normal physical and social development for timing and progression of puberty, starting between 11 and 12 years of age and increasing over 2 to 3 years. This regimen improves socialization and growth, and optimizes uterine and bone health. Neurocognitive benefits are inconclusive.

When available, low-dose E₂ administered by a systemic route is preferred, and evidence supports its effectiveness and theoretical benefits. When TD E₂ is not available, or compliance is an issue, evidence supports use of oral micronized E₂ or depot E₂ preparations. Only when these forms of E₂ are unavailable should other forms of estrogen be prescribed. Progestin should be added once vaginal bleeding occurs or after 2 years of estrogen treatment. At that time, some women prefer the ease of use of an oral combination of estrogen and progestin. Some preparations are safer than others, and availability varies by country, but, ordinarily, the benefit of good compliance to a chosen regimen outweighs the risks. Treatment is monitored by patient satisfaction and growth and development measures.

Acknowledgments

This work started during the 2016 International Consensus Meeting, and we thank all the delegates for their discussion of these topics.

Correspondence and Reprint Requests: Karen O. Klein, MD, Rady Children's Hospital, 3020 Children's Way, MC 5103, San Diego, California 92123. E-mail: kklein@ucsd.edu.

Disclosure Summary: The authors have nothing to disclose.

References

1. Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, Lin AE, Mauras N, Quigley CA, Rubin K, Sandberg DE, Sas TCJ, Silberbach M, Söderström-Anttila V, Stochholm K, van Alfen-van der Velden JA, Woelfle J, Backeljauw PF; International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. *Eur J Endocrinol*. 2017;177(3):G1–G70.
2. Cameron-Pimblett A, La Rosa C, King TFJ, Davies MC, Conway GS. The Turner syndrome life course project: karyotype-phenotype analyses across the lifespan. *Clin Endocrinol (Oxf)*. 2017;87(5):532–538.
3. Torres-Santiago L, Mericq V, Taboada M, Unanue N, Klein KO, Singh R, Hossain J, Santen RJ, Ross JL, Mauras N. Metabolic effects of oral versus transdermal 17 β -estradiol (E₂): a randomized clinical trial in girls with Turner syndrome. *J Clin Endocrinol Metab*. 2013;98(7):2716–2724.
4. Mohammed K, Abu Dabrh AM, Benkhadra K, Al Nofal A, Carranza Leon BG, Prokop LJ, Montori VM, Faubion SS, Murad MH. Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2015;100(11):4012–4020.
5. Canonico M, Carcaillon L, Plu-Bureau G, Oger E, Singh-Manoux A, Tubert-Bitter P, Elbaz A, Scarabin PY. Postmenopausal hormone therapy and risk of stroke impact of the route of estrogen administration and type of progestogen. *Stroke*. 2016;47(7):1734–1741.
6. Tanaka T, Igarashi Y, Ozono K, Ohyama K, Ogawa M, Osada H, Onigata K, Kanzaki S, Kohno H, Seino Y, Takahashi H, Tajima T, Tachibana K, Tanaka H, Nishi Y, Hasegawa T, Fujita K, Yorifuji T, Horikawa R, Yokoya S. Frequencies of spontaneous breast development and spontaneous menarche in Turner syndrome in Japan. *Clin Pediatr Endocrinol*. 2015;24(4):167–173.
7. Negreiros LP, Bolina ER, Guimarães MM. Pubertal development profile in patients with Turner syndrome. *J Pediatr Endocrinol Metab*. 2014;27(9-10):845–849.
8. Pasquino AM, Passeri F, Pucarelli I, Segni M, Municchi G; Italian Study Group for Turner's Syndrome. Spontaneous pubertal development in Turner's syndrome. *J Clin Endocrinol Metab*. 1997;82(6):1810–1813.
9. Hagen CP, Main KM, Kjaergaard S, Juul A. FSH, LH, inhibin B and estradiol levels in Turner syndrome depend on age and karyotype: longitudinal study of 70 Turner girls with or without spontaneous puberty. *Hum Reprod*. 2010;25(12):3134–3141.
10. Fechner PY, Davenport ML, Qualy RL, Ross JL, Gunther DF, Eugster EA, Huseman C, Zagar AJ, Quigley CA; Toddler Turner Study Group. Differences in follicle-stimulating hormone secretion between 45,X monosomy Turner syndrome and 45,X/46,XX mosaicism are evident at an early age. *J Clin Endocrinol Metab*. 2006;91(12):4896–4902.
11. Conte FA, Grumbach MM, Kaplan SL. A biphasic pattern of gonadotropin secretion in patients with the syndrome of gonadal dysgenesis. *J Clin Endocrinol Metab*. 1975;40(4):670–674.
12. Lunding SA, Aksglaede L, Anderson RA, Main KM, Juul A, Hagen CP, Pedersen AT. AMH as predictor of premature ovarian insufficiency: a longitudinal study of 120 Turner syndrome patients. *J Clin Endocrinol Metab*. 2015;100(7):E1030–E1038.
13. Rosenfield RL, Perovic N, Devine N, Mauras N, Moshang T, Root AW, Sy JP. Optimizing estrogen replacement treatment in Turner syndrome. *Pediatrics*. 1998;102(2 Pt 3):486–488.

14. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites of 17 β -estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. *Endocrinology*. 2003;144(8):3382–3398.
15. Lépine J, Bernard O, Plante M, Têtu B, Pelletier G, Labrie F, Bélanger A, Guillemette C. Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphosphoglucuronosyltransferases expressed in endometrium. *J Clin Endocrinol Metab*. 2004;89(10):5222–5232.
16. Lévesque E, Turgeon D, Carrier JS, Montminy V, Beaulieu M, Bélanger A. Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. *Biochemistry*. 2001;40(13):3869–3881.
17. Ankarberg-Lindgren C, Elfving M, Wikland KA, Norjavaara E. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. *J Clin Endocrinol Metab*. 2001;86(7):3039–3044.
18. Van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulmsa T, Stokvis-Brantsma WH, Rouwé CW, Reeser HM, Gerwer WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL. Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. *J Clin Endocrinol Metab*. 2003;88(3):1119–1125.
19. Piippo S, Lenko H, Kainulainen P, Sipilä I. Use of percutaneous estrogen gel for induction of puberty in girls with Turner syndrome. *J Clin Endocrinol Metab*. 2004;89(7):3241–3247.
20. Soriano-Guillen L, Coste J, Ecosse E, Léger J, Tauber M, Cabrol S, Nicolino M, Brauner R, Chaussain JL, Carel JC. Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone. *J Clin Endocrinol Metab*. 2005;90(9):5197–5204.
21. Rosenfield RL, Devine N, Hunold JJ, Mauras N, Moshang T Jr, Root AW. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. *J Clin Endocrinol Metab*. 2005;90(12):6424–6430.
22. Nabhan ZM, Dimeglio LA, Qi R, Perkins SM, Eugster EA. Conjugated oral versus transdermal estrogen replacement in girls with Turner syndrome: a pilot comparative study. *J Clin Endocrinol Metab*. 2009;94(6):2009–2014.
23. Bannink EM, van Sassen C, van Buuren S, de Jong FH, Lequin M, Mulder PG, de Muinck Keizer-Schrama SM. Puberty induction in Turner syndrome: results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels. *Clin Endocrinol (Oxf)*. 2009;70(2):265–273.
24. Ross JL, Quigley CA, Cao D, Feuillan P, Kowal K, Chipman JJ, Cutler GB Jr. Growth hormone plus childhood low-dose estrogen in Turner's syndrome. *N Engl J Med*. 2011;364(13):1230–1242.
25. Quigley CA, Wan X, Garg S, Kowal K, Cutler GB Jr, Ross JL. Effects of low-dose estrogen replacement during childhood on pubertal development and gonadotropin concentrations in patients with Turner syndrome: results of a randomized, double-blind, placebo-controlled clinical trial. *J Clin Endocrinol Metab*. 2014;99(9):E1754–E1764.
26. Perry RJ, Gault EJ, Paterson WF, Dunger DB, Donaldson MD. Effect of oxandrolone and timing of oral ethinylestradiol initiation on pubertal progression, height velocity and bone maturation in the UK Turner study. *Horm Res Paediatr*. 2014;81(5):298–308.
27. Çakır ED, Sağlam H, Eren E, Özgür T, Tarım OF. Retrospective evaluation of pubertal development and linear growth of girls with Turner syndrome treated with oral and transdermal estrogen. *J Pediatr Endocrinol Metab*. 2015;28(11-12):1219–1226.
28. Misra M, Katzman D, Miller KK, Mendes N, Snelgrove D, Russell M, Goldstein MA, Ebrahimi S, Clauss L, Weigel T, Mickley D, Schoenfeld DA, Herzog DB, Klibanski A. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. *J Bone Miner Res*. 2011;26(10):2430–2438.
29. Bondy CA; Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. *J Clin Endocrinol Metab*. 2007;92(1):10–25.
30. Shifren JL, Gass MLS; NAMS Recommendations for Clinical Care of Midlife Women Working Group. The North American Menopause Society recommendations for clinical care of midlife women. *Menopause*. 2014;21(10):1038–1062.
31. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. [Erratum appears in *Breast Cancer Res Treat*. 2008; 107(2):307–308] *Breast Cancer Res Treat*. 2008;107(1):103–111.
32. Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. *Endocr Rev*. 2013;34(2):171–208.
33. Practice Committee of the American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. *Fertil Steril*. 2017;107(1):43–51.
34. Devineni D, Skee D, Vaccaro N, Massarella J, Janssens L, LaGuardia KD, Leung AT. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. *J Clin Pharmacol*. 2007;47(4):497–509.
35. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH; Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. *J Clin Endocrinol Metab*. 2010;95(7 Suppl 1):s1–s66.
36. Rosenfield RL, DiMeglio LA, Mauras N, Ross J, Shaw ND, Greeley SA, Haymond M, Rubin K, Rhodes ET. Commentary: launch of a quality improvement network for evidence-based management of uncommon pediatric endocrine disorders: Turner syndrome as a prototype. *J Clin Endocrinol Metab*. 2015;100(4):1234–1236.
37. Rosenfield RL, Fang VS, Dupon C, Kim MH, Refetoff S. The effects of low doses of depot estradiol and testosterone in teenagers with ovarian failure and Turner's syndrome. *J Clin Endocrinol Metab*. 1973;37(4):574–580.
38. Rosenfield RL, Bordini B, Yu C. Comparison of detection of normal puberty in girls by a hormonal sleep test and a gonadotropin-releasing hormone agonist test. *J Clin Endocrinol Metab*. 2013;98(4):1591–1601.
39. Taboada M, Santen R, Lima J, Hossain J, Singh R, Klein KO, Mauras N. Pharmacokinetics and pharmacodynamics of oral and transdermal 17 β estradiol in girls with Turner syndrome. *J Clin Endocrinol Metab*. 2011;96(11):3502–3510.
40. Trolle C, Hjerrild B, Cleemann L, Mortensen KH, Gravholt CH. Sex hormone replacement in Turner syndrome. *Endocrine*. 2012;41(2):200–219.
41. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ. Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2015;100(11):3975–4011.
42. Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. *N Engl J Med*. 2017;377(23):2228–2239.
43. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. *Menopause*. 2012;19(3):257–271.
44. Ostberg JE, Storry C, Donald AE, Attar MJN, Halcox JPJ, Conway GS. A dose-response study of hormone replacement in

- young hypogonadal women: effects on intima media thickness and metabolism. *Clin Endocrinol (Oxf)*. 2007;66(4):557–564.
45. Koulouri O, Ostberg J, Conway GS. Liver dysfunction in Turner's syndrome: prevalence, natural history and effect of exogenous oestrogen. *Clin Endocrinol (Oxf)*. 2008;69(2):306–310.
46. Gravholt CH, Naeraa RW, Andersson AM, Christiansen JS, Skakkebaek NE. Inhibin A and B in adolescents and young adults with Turner's syndrome and no sign of spontaneous puberty. *Hum Reprod*. 2002;17(8):2049–2053.
47. Taylor AE, Adams JM, Mulder JE, Martin KA, Sluss PM, Crowley WF Jr. A randomized, controlled trial of estradiol replacement therapy in women with hypergonadotropic amenorrhea. *J Clin Endocrinol Metab*. 1996;81(10):3615–3621.
48. Crofton PM, Evans N, Bath LE, Warner P, Whitehead TJ, Critchley HO, Kelnar CJ, Wallace WH. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. *Clin Endocrinol (Oxf)*. 2010;73(6):707–714.
49. Gault EJ, Perry RJ, Cole TJ, Casey S, Paterson WF, Hindmarsh PC, Betts P, Dunger DB, Donaldson MD; British Society for Paediatric Endocrinology and Diabetes. Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial. *BMJ*. 2011;342(apr14 1):d1980.
50. Mauras N, Shulman D, Hsiang HY, Balagopal P, Welch S. Metabolic effects of oral versus transdermal estrogen in growth hormone-treated girls with Turner syndrome. *J Clin Endocrinol Metab*. 2007;92(11):4154–4160.
51. Gravholt CH, Naeraa RW, Fisker S, Christiansen JS. Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth factor axis aberrations in adult Turner's syndrome, with important modulations by treatment with 17 beta-estradiol. *J Clin Endocrinol Metab*. 1997;82(8):2570–2577.
52. Kam GY, Leung KC, Baxter RC, Ho KK. Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. *J Clin Endocrinol Metab*. 2000;85(5):1918–1922.
53. Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. *J Clin Endocrinol Metab*. 1991;72(2):374–381.
54. Jospe N, Orłowski CC, Furlanetto RW. Comparison of transdermal and oral estrogen therapy in girls with Turner's syndrome. *J Pediatr Endocrinol Metab*. 1995;8(2):111–116.
55. Gravholt CH, Naeraa RW, Nyholm B, Gerdes LU, Christiansen E, Schmitz O, Christiansen JS. Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner's syndrome. The impact of sex hormone replacement. *Diabetes Care*. 1998;21(7):1062–1070.
56. Gussinyé M, Terrades P, Yeste D, Vicens-Calvet E, Carrascosa A. Low areal bone mineral density values in adolescents and young adult Turner syndrome patients increase after long-term transdermal estradiol therapy. *Horm Res*. 2000;54(3):131–135.
57. Guttmann H, Weiner Z, Nikolski E, Ish-Shalom S, Itskovitz-Eldor J, Aviram M, Reisner S, Hochberg Z. Choosing an oestrogen replacement therapy in young adult women with Turner syndrome. *Clin Endocrinol (Oxf)*. 2001;54(2):159–164.
58. Naeraa RW, Gravholt CH, Kastrup KW, Svenstrup B, Christiansen JS. Morning versus evening administration of estradiol to girls with Turner syndrome receiving growth hormone: impact on growth hormone and metabolism. A randomized placebo-controlled crossover study. *Acta Paediatr*. 2001;90(5):526–531.
59. Alves ST, Gallichio CT, Guimarães MM. Insulin resistance and body composition in Turner syndrome: effect of sequential change in the route of estrogen administration. *Gynecol Endocrinol*. 2006;22(10):590–594.
60. Reinehr T, Lindberg A, Toschke C, Cara J, Chrysis D, Camacho-Hübner C. Weight gain in Turner Syndrome: association to puberty induction? — longitudinal analysis of KIGS data. *Clin Endocrinol (Oxf)*. 2016;85(1):85–91.
61. Roulot D, Degott C, Chazouillères O, Oberti F, Calès P, Carbonell N, Benferhat S, Bresson-Hadni S, Valla D. Vascular involvement of the liver in Turner's syndrome. *Hepatology*. 2004;39(1):239–247.
62. Ostberg JE, Thomas EL, Hamilton G, Attar MJ, Bell JD, Conway GS. Excess visceral and hepatic adipose tissue in Turner syndrome determined by magnetic resonance imaging: estrogen deficiency associated with hepatic adipose content. *J Clin Endocrinol Metab*. 2005;90(5):2631–2635.
63. Gravholt CH, Poulsen HE, Ott P, Christiansen JS, Vilstrup H. Quantitative liver functions in Turner syndrome with and without hormone replacement therapy. *Eur J Endocrinol*. 2007;156(6):679–686.
64. Larizza D, Locatelli M, Vitali L, Viganò C, Calcaterra V, Tinelli C, Sommaruga MG, Bozzini A, Campani R, Severi F. Serum liver enzymes in Turner syndrome. *Eur J Pediatr*. 2000;159(3):143–148.
65. Elsheikh M, Hodgson HJ, Wass JA, Conway GS. Hormone replacement therapy may improve hepatic function in women with Turner's syndrome. *Clin Endocrinol (Oxf)*. 2001;55(2):227–231.
66. El-Mansoury M, Berntorp K, Bryman I, Hanson C, Innala E, Karlsson A, Landin-Wilhelmsen K. Elevated liver enzymes in Turner syndrome during a 5-year follow-up study. *Clin Endocrinol (Oxf)*. 2008;68(3):485–490.
67. Albareda MM, Gallego A, Enríquez J, Rodríguez JL, Webb SM. Biochemical liver abnormalities in Turner's syndrome. *Eur J Gastroenterol Hepatol*. 1999;11(9):1037–1039.
68. Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. *J Clin Epidemiol*. 1998;51(2):147–158.
69. Baronio F, Mazzanti L, Girtler Y, Tamburrino F, Lupi F, Longhi S, Fanolla A, Radetti G. The influence of GH treatment on glucose homeostasis in girls with Turner syndrome: a 7-year study. *J Clin Endocrinol Metab*. 2017;102(3):878–883.
70. Cleemann L, Holm K, Kobbarnagel H, Kristensen B, Skouby SO, Jensen AK, Gravholt CH. Dosage of estradiol, bone and body composition in Turner syndrome: a 5-year randomized controlled clinical trial. *Eur J Endocrinol*. 2017;176(2):233–242.
71. Cartwright B, Robinson J, Seed PT, Fogelman I, Rymer J. Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomized controlled trial of the effects on bone mineral density. *J Clin Endocrinol Metab*. 2016;101(9):3497–3505.
72. Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck Keizer-Schrama S, Hogervorst E, Janse F, Liao L, Vlasisavljevic V, Zillikens C, Vermeulen N; European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. ESHRE Guideline: management of women with premature ovarian insufficiency. *Hum Reprod*. 2016;31(5):926–937.
73. Herrmann M, Seibel MJ. The effects of hormonal contraceptives on bone turnover markers and bone health. *Clin Endocrinol (Oxf)*. 2010;72(5):571–583.
74. Lopez LM, Grimes DA, Schulz KF, Curtis KM, Chen M. Steroidal contraceptives: effect on bone fractures in women. *Cochrane Database Syst Rev*. 2014;2014(6):CD006033.
75. Paterson WF, Hollman AS, Donaldson MD. Poor uterine development in Turner syndrome with oral oestrogen therapy. *Clin Endocrinol (Oxf)*. 2002;56(3):359–365.
76. Bakalov VK, Shawker T, Cenicerros I, Bondy CA. Uterine development in Turner syndrome. *J Pediatr*. 2007;151(5):528–531.
77. Rodrigues EB, Braga J, Gama M, Guimarães MM. Turner syndrome patients' ultrasound profile. *Gynecol Endocrinol*. 2013;29(7):704–706.

78. Elsefdy HH, Hamza RT, Farghaly MH, Ghazy MS. Uterine development in patients with Turner syndrome: relation to hormone replacement therapy and karyotype. *J Pediatr Endocrinol Metab.* 2012;25(5-6):441–445.
79. Cleemann L, Holm K, Fallentin E, Skouby SO, Smedegaard H, Møller N, Borch-Christensen H, Jeppesen EM, Wieslander SB, Andersson AM, Cohen A, Højbjerg Gravholt C. Uterus and ovaries in girls and young women with Turner syndrome evaluated by ultrasound and magnetic resonance imaging. *Clin Endocrinol (Oxf).* 2011;74(6):756–761.
80. Foudila T, Söderström-Anttila V, Hovatta O. Turner's syndrome and pregnancies after oocyte donation. *Hum Reprod.* 1999;14(2):532–535.
81. Langrish JP, Mills NL, Bath LE, Warner P, Webb DJ, Kelnar CJ, Critchley HOD, Newby DE, Wallace WHB. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. *Hypertension.* 2009;53(5):805–811.
82. Mortensen KH, Andersen NH, Gravholt CH. Cardiovascular phenotype in Turner syndrome—integrating cardiology, genetics, and endocrinology. *Endocr Rev.* 2012;33(5):677–714.
83. Stachenfeld NS, DiPietro L, Palter SF, Nadel ER. Estrogen influences osmotic secretion of AVP and body water balance in postmenopausal women. *Am J Physiol.* 1998;274(1 Pt 2):R187–R195.
84. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. *J Clin Endocrinol Metab.* 1995;80(6):1816–1821.
85. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. *BMJ.* 2010;340(jun03 4):c2519.
86. Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, Green J, Reeves GK; Million Women Study Collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. *J Thromb Haemost.* 2012;10(11):2277–2286.
87. Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. *Climacteric.* 2016;19(2):109–150.
88. Ross JL, Roeltgen D, Feuillan P, Kushner H, Cutler GB Jr. Effects of estrogen on nonverbal processing speed and motor function in girls with Turner's syndrome. *J Clin Endocrinol Metab.* 1998;83(9):3198–3204.
89. Ross JL, Roeltgen D, Feuillan P, Kushner H, Cutler GB Jr. Use of estrogen in young girls with Turner syndrome: effects on memory. *Neurology.* 2000;54(1):164–170.
90. Ross JL, McCauley E, Roeltgen D, Long L, Kushner H, Feuillan P, Cutler GB Jr. Self-concept and behavior in adolescent girls with Turner syndrome: potential estrogen effects. *J Clin Endocrinol Metab.* 1996;81(3):926–931.
91. Ross JL, Stefanatos GA, Kushner H, Zinn A, Bondy C, Roeltgen D. Persistent cognitive deficits in adult women with Turner syndrome. *Neurology.* 2002;58(2):218–225.
92. Ross JL, Stefanatos GA, Kushner H, Bondy C, Nelson L, Zinn A, Roeltgen D. The effect of genetic differences and ovarian failure: intact cognitive function in adult women with premature ovarian failure versus Turner syndrome. *J Clin Endocrinol Metab.* 2004;89(4):1817–1822.
93. Carel JC, Elie C, Ecosse E, Tauber M, Léger J, Cabrol S, Nicolino M, Brauner R, Chaussain JL, Coste J. Self-esteem and social adjustment in young women with Turner syndrome—influence of pubertal management and sexuality: population-based cohort study. *J Clin Endocrinol Metab.* 2006;91(8):2972–2979.
94. Sheaffer AT, Lange E, Bondy CA. Sexual function in women with Turner syndrome. *J Womens Health (Larchmt).* 2008;17(1):27–33.
95. Fjermestad KW, Naess EE, Bahr D, Gravholt CH. A 6-year follow-up survey of health status in middle-aged women with Turner syndrome. *Clin Endocrinol (Oxf).* 2016;85(3):423–429.
96. Bannink EM, Raat H, Mulder PG, de Muinck Keizer-Schrama SM. Quality of life after growth hormone therapy and induced puberty in women with Turner syndrome. *J Pediatr.* 2006;148(1):95–101.
97. Nilsson KO, Albertsson-Wikland K, Alm J, Aronson S, Gustafsson J, Hagenäs L, Häger A, Ivarsson SA, Karlberg J, Kriström B, Marcus C, Moell C, Ritzen M, Tuvemo T, Wattsgård C, Westgren U, Westphal O, Aman J. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. *J Clin Endocrinol Metab.* 1996;81(2):635–640.
98. Menke LA, Sas TC, de Muinck Keizer-Schrama SM, Zandwijken GR, de Ridder MA, Odink RJ, Jansen M, Delemarre-van de Waal HA, Stokvis-Brantsma WH, Waelkens JJ, Westerlaken C, Reeser HM, van Trotsenburg AS, Gevers EF, van Buuren S, Dejonckere PH, Hokken-Koelega AC, Otten BJ, Wit JM. Efficacy and safety of oxandrolone in growth hormone-treated girls with Turner syndrome. *J Clin Endocrinol Metab.* 2010;95(3):1151–1160.
99. Zeger MP, Shah K, Kowal K, Cutler GB Jr, Kushner H, Ross JL. Prospective study confirms oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with Turner syndrome. *Horm Res Paediatr.* 2011;75(1):38–46.
100. Sas TC, Gault EJ, Bardsley MZ, Menke LA, Freriks K, Perry RJ, Otten BJ, de Muinck Keizer-Schrama SM, Timmers H, Wit JM, Ross JL, Donaldson MD. Safety and efficacy of oxandrolone in growth hormone-treated girls with Turner syndrome: evidence from recent studies and recommendations for use. *Horm Res Paediatr.* 2014;81(5):289–297.
101. Freriks K, Sas TC, Traas MA, Netea-Maier RT, den Heijer M, Hermus AR, Wit JM, van Alfen-van der Velden JA, Otten BJ, de Muinck Keizer-Schrama SM, Gotthardt M, Dejonckere PH, Zandwijken GR, Menke LA, Timmers HJ. Long-term effects of previous oxandrolone treatment in adult women with Turner syndrome. *Eur J Endocrinol.* 2012;168(1):91–99.
102. Sheanon NM, Backeljauw PF. Effect of oxandrolone therapy on adult height in Turner syndrome patients treated with growth hormone: a meta-analysis. *Int J Pediatr Endocrinol.* 2015;2015(1):18.